Travere Therapeutics - TVTX - Stock Price Today - Zacks

Jan 7, 2025 · Get the latest Travere Therapeutics, Inc TVTX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. ... licensed by Zacks Investment Research, Inc. from …

$18
OFF

Travere Therapeutics (TVTX) - Zacks Investment Research

2 weeks from now

Jan 6, 2025 · The forecasts for Travere Therapeutics, Inc. (TVTX) range from a low of $18 to a high of $42. The average price target represents a increase of $44.22 from the last closing …

zacks.com

27%
OFF

Should I Buy Travere Therapeutics (TVTX) - Zacks

2 weeks from now

2 days ago · Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates 10/31/24-7:25AM EST Zacks Wall Street Analysts See a 26.27% Upside in Travere (TVTX): Can the …

zacks.com

6%
OFF

Travere (TVTX) Surges 11.6%: Is This An Indication Of Further Gains?

2 weeks from now

Oct 7, 2024 · Travere Therapeutics (TVTX) shares soared 11.6% in the last trading session to close at $15.23. The move was backed by solid volume with far more shares changing hands …

nasdaq.com

56%
OFF

Wall Street Analysts Believe Travere (TVTX) Could Rally 42.56%: …

2 weeks from now

Jan 8, 2025 · Zacks Equity Research . ... 9:55 AM 4 min read. Travere Therapeutics (TVTX) closed the last trading session at $19.08, gaining 1.8% over the past four weeks, but there …

yahoo.com

27%
OFF

Wall Street Analysts See A 26.27% Upside In Travere (TVTX

2 weeks from now

Oct 23, 2024 · Travere Therapeutics (TVTX) closed the last trading session at $17.97, gaining 23.4% over the past four weeks, but there could be plenty of upside left in the stock if short …

nasdaq.com

1%
OFF

Pacira (PCRX) Soars 11.1%: Is Further Upside Left In The Stock?

2 weeks from now

2 days ago · One other stock in the same industry, Travere Therapeutics (TVTX), finished the last trading session 4.8% lower at $18.09. TVTX has returned 6.1% over the past month. ... Zacks …

yahoo.com

5%
OFF

Travere (TVTX) Q3 Earnings: How Key Metrics Compare To Wall

2 weeks from now

Oct 31, 2024 · Travere Therapeutics (TVTX) reported $62.9 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 69.5%. ... Zacks is the …

nasdaq.com

$23.00
OFF

Travere Therapeutics (NASDAQ:TVTX) Coverage Initiated By …

2 weeks from now

3 days ago · Citigroup cut their price objective on Travere Therapeutics from $23.00 to $19.00 and set a “buy” rating for the company in a research report on Friday, September 27th.

etfdailynews.com

$27.00
OFF

Wells Fargo Reaffirms Their Buy Rating On Travere Therapeutics …

2 weeks from now

1 day ago · Wells Fargo analyst Mohit Bansal maintained a Buy rating on Travere Therapeutics (TVTX – Research Report) on January 10 and set a price target of $27.00. The company’s …

businessinsider.com

$28.56
OFF

Stifel Nicolaus Sticks To Its Hold Rating For Travere Therapeutics …

2 weeks from now

1 day ago · Travere Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $28.56. See the top stocks recommended by analysts >> TVTX market cap is …

businessinsider.com

1%
OFF

Wall Street Analysts Think Travere (TVTX) Could Surge 66.29

2 weeks from now

Jan 17, 2024 · Shares of Travere Therapeutics (TVTX) have gained 2.1% over the past four weeks to close the last trading session at $8.90, but there could still be a solid upside left in …

nasdaq.com

$45
OFF

Travere Therapeutics Price Target Raised To $45 From $41 At …

2 weeks from now

1 day ago · Guggenheim raised the firm’s price target on Travere Therapeutics (TVTX) to $45 from $41 and keeps a Buy rating on the shares. ... the analyst tells investors in a research …

businessinsider.com

$74
OFF

Promising Financial Outlook And Strategic ... - Markets Insider

2 weeks from now

2 days ago · Read More on TVTX: Travere Therapeutics sees Q4 net product sales $74M; Travere Therapeutics sees FY24 net product sales approx $227M; MHRA approves Travere’s …

businessinsider.com

$0.70
OFF

Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue …

2 weeks from now

Oct 31, 2024 · Travere Therapeutics (TVTX Quick Quote TVTX - Free Report) came out with a quarterly loss of $0.70 per share in line with the Zacks Consensus Estimate.This compares to …

zacks.com

FAQs about Travere Therapeutics - TVTX - Stock Price Today - Zacks Coupon?

Is Travere Therapeutics (tvtx) a good stock to buy?

Travere Therapeutics (TVTX) closed the last trading session at $19.08, gaining 1.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $27.20 indicates a 42.6% upside potential. ...

Is Travere Therapeutics a good stock to buy?

Barclays increased their price target on Travere Therapeutics from $18.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, November 1st. Citigroup cut their price objective on Travere Therapeutics from $23.00 to $19.00 and set a “buy” rating for the company in a research report on Friday, September 27th. ...

Where can I find information about Travere Therapeutics?

The Investor Relations website contains information about Travere Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. ...

Does Travere therapeutics have a Billion Dollar Secret?

No data available. Better trading starts here. The Zacks Rank has been called the Billion Dollar Secret. Click here to watch the full series. Travere Therapeutics Inc. is a biopharmaceutical company. It engages to identify, develop and deliver life-changing therapies. ...

What is Travere Therapeutics' mission?

Travere Therapeutics is a biopharmaceutical company whose mission is to identify, develop, and deliver life-changing therapies to people living with rare disease. Data Provided by Refinitiv. Minimum 15 minutes delayed. © 2024 Travere Therapeutics, Inc. All rights reserved. For US audiences. ...

Should you buy Thompson CFA & Travere Therapeutics (tvtx)?

According to TipRanks, Thompson CFA has an average return of 2.4% and a 44.94% success rate on recommended stocks. Travere Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $28.56. TVTX market cap is currently $1.57B and has a P/E ratio of -3.97. ...